2024
Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use
Chupp G, Murphy K, Gandhi H, Gilbert I, Bleecker E. Asthma control in the United States Relationships between short-acting β2-agonist and systemic corticosteroid use. Annals Of Allergy Asthma & Immunology 2024, 133: 302-309. PMID: 38740134, DOI: 10.1016/j.anai.2024.05.003.Peer-Reviewed Original ResearchMild to moderate diseaseSystemic corticosteroidsMild-to-moderateSevere asthmaUncontrolled asthmaSystemic corticosteroid exposureSystemic corticosteroid useAsthma control assessmentCorticosteroid useExacerbation historyRetrospective analysisSABA useUS patientsPrescription fillsPatientsLongitudinal accessAsthma controlDisease severityAsthmaDiseaseExacerbationPearson correlation coefficientHigh symptom burdenPatient severitySymptom burden
2023
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES
MOORE W, LUGOGO N, CHUPP G, MARTIN N, AMBROSE C, COOK W, ACKERT J. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA WITH COMORBID GASTROESOPHAGEAL REFLUX DISEASE: A POOLED ANALYSIS OF THE PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2023, 164: a4-a7. DOI: 10.1016/j.chest.2023.07.073.Peer-Reviewed Original ResearchLONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
CHUPP G, LUGOGO N, WECHSLER M, LAWSON K, LINDSLEY A, SPAHN J, AMBROSE C. LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX. CHEST Journal 2023, 164: a9-a14. DOI: 10.1016/j.chest.2023.07.075.Peer-Reviewed Original ResearchClinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years
Brusselle G, Lougheed M, Canonica G, Munoz-Esquerre M, Heaney L, Price R, Howarth P, Raimondi A, Gardiner F, Chupp G, Welte T. Clinical Remission Achievement in Severe Asthma Following Mepolizumab Treatment: Results From the REALITI-A Study at 2 Years. 2023, a5985-a5985. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5985.Peer-Reviewed Original ResearchEfficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study
Kraft M, Chupp G, Reeh K, Lindsley A, Cook B, Hunter G, Ambrose C. Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study. 2023, a4751-a4751. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4751.Peer-Reviewed Original ResearchReal-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study
Chupp G, Heaney L, Price R, Brusselle G, Gardiner F, Raimondi A, Chaudhuri R, Howarth P. Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Journal Of Allergy And Clinical Immunology 2023, 151: ab20. DOI: 10.1016/j.jaci.2022.12.066.Peer-Reviewed Original Research
2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
Corren J, Wechsler M, Chupp G, Roseti S, Hellqvist Å, Martin N, Llanos J, Ambrose C, Colice G. Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 943-945.e2. PMID: 36375743, DOI: 10.1016/j.jaip.2022.10.042.Peer-Reviewed Original ResearchEFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES
CORREN J, WECHSLER M, CHUPP G, AMBROSE C, ROSETI S, HELLQVIST Å, ACKERT J, MARTIN N, COLICE G. EFFICACY OF TEZEPELUMAB IN PATIENTS WITH UNCONTROLLED ASTHMA DESPITE RECEIVING TREATMENT FOR MODERATE OR SEVERE DISEASE: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR STUDIES. CHEST Journal 2022, 162: a21-a22. DOI: 10.1016/j.chest.2022.08.018.Peer-Reviewed Original ResearchEndothelial Thrombopoietin Receptor Controls Eosinophil Trafficking in Asthma and Chronic Rhinosinusitis
Korde A, Haslip M, Ahangari F, Pober J, Chupp G, Manes P, Gonzalez A, Takyar S. Endothelial Thrombopoietin Receptor Controls Eosinophil Trafficking in Asthma and Chronic Rhinosinusitis. 2022, a5684-a5684. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5684.Peer-Reviewed Original ResearchMepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma
Chupp G, Lee J, Liu M, Schleich F, Heaney L, Ribas C, Carrillo-Díaz T, Aparicio M, Moragón E, Sanchez-Herrero M, Gardiner F, Alfonso-Cristancho R, Jakes R, Price R, Howarth P. Mepolizumab Demonstrates Real-world Clinical Effectiveness in both Type 2 Biomarker High and Type 2 Biomarker Low Patients with Severe Asthma. Journal Of Allergy And Clinical Immunology 2022, 149: ab318. DOI: 10.1016/j.jaci.2021.12.019.Peer-Reviewed Original Research
2021
D010 CAPTAIN STUDY: EFFECTS OF BASELINE IGE LEVELS ON TRIPLE THERAPY RESPONSE IN INADEQUATELY CONTROLLED ASTHMA
Oppenheimer J, Abott C, Chang S, Chupp G, Crawford J, Mannino D, Win P. D010 CAPTAIN STUDY: EFFECTS OF BASELINE IGE LEVELS ON TRIPLE THERAPY RESPONSE IN INADEQUATELY CONTROLLED ASTHMA. Annals Of Allergy Asthma & Immunology 2021, 127: s14. DOI: 10.1016/j.anai.2021.08.048.Peer-Reviewed Original ResearchEffect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR
Korn S, Bourdin A, Chupp G, Colice G, Ambrose C, Kmita K, Llanos-Ackert J, Molfino N, Cook B. Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR. 2021, oa1198. DOI: 10.1183/13993003.congress-2021.oa1198.Peer-Reviewed Original ResearchCAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA
Kerstjens H, Abbott C, Boulet L, Chang S, Chupp G, Crawford J, Hanania N, Nathan R, Oppenheimer J, Pizzichini E, Sagara H, Busse W. CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA. 2021, pa3386. DOI: 10.1183/13993003.congress-2021.pa3386.Peer-Reviewed Original ResearchResults of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT)
Chupp G, Beeh K, Jauhiainen A, Necander S, Brown M, Wählby Hamrén U, Forsman H, Kurdyukova Y, Steele J, Astbury C, Psallidas I. Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT). 2021, a1202-a1202. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1202.Peer-Reviewed Original ResearchEfficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study
Corren J, Bourdin A, Chupp G, Israel E, Ambrose C, Llanos Ackert J, Kmita K, Cook B, Colice G, Menzies-Gow A. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Baseline Blood Eosinophil Count and Fractional Exhaled Nitric Oxide Level: Results from the NAVIGATOR Phase 3 Study. 2021, a1198-a1198. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1198.Peer-Reviewed Original ResearchReductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study
Bourdin A, Menzies-Gow A, Chupp G, Israel E, Hellqvist, Hunter G, Ambrose C, Llanos Ackert J, Colice G, Cook B, Corren J. Reductions in Asthma Exacerbation-Related Hospitalizations and Emergency Department Visits in Patients with Severe, Uncontrolled Asthma Treated with Tezepelumab: Results from the Phase 3 NAVIGATOR Study. 2021, a1203-a1203. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1203.Peer-Reviewed Original ResearchIntegrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years
Bourdin A, Korn S, Chupp G, Cosio B, Arbetter D, Shah M, Garcia Gil E. Integrated Safety and Efficacy Among Patients with Severe Asthma Receiving Benralizumab for Up to Five Years. 2021, a1205-a1205. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1205.Peer-Reviewed Original ResearchEfficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Griffiths J, Hellqvist Å, Bowen K, Kaur P, Almqvist G, Ponnarambil S, Colice G. Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study. Journal Of Allergy And Clinical Immunology 2021, 147: ab249. DOI: 10.1016/j.jaci.2020.12.050.Peer-Reviewed Original Research
2020
Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure
Murphy K, Chipps B, Beuther D, Wise R, McCann W, Gilbert I, Eudicone J, Gandhi H, Harding G, Coyne K, Zeiger R, Board P, Kobernick A, Mohammad A, Cherry A, Fein A, Gaines A, Ramsey A, Michaud A, Palmer A, Kim A, Smith A, White A, Ricci A, Kettelhut B, Modena B, Stone B, Rolston B, Schnapf B, Krajicek B, Kraft C, Hopkins C, Natalie C, Anderson C, Czajkowski C, Arce D, Hamlin D, Hill D, Mares D, Pham D, Liao D, Simmons D, Johnson D, Jhaveri D, Maselli D, Kerwin E, Schuman E, Sher E, Bleecker E, Rakowski E, Hsu F, Averill F, Barsanti F, Gross G, Chupp G, Head G, Nasir H, Lee H, Barjaktarevic I, Cook J, Krainson J, Pearl J, Bellak J, Perez-Fernandez J, Rehm J, Trevor J, Most J, Hanson J, Blessing-Moore J, Biller J, Gedell J, Southard J, Chancellor J, Ilowite J, Romeo J, Mercado J, Fisher J, Greiwe J, Gregory K, Nadeau K, Shenoy K, Tan L, Stefanowicz L, Humes L, Bowers L, O’Connor M, Perez M, White M, Hegewald M, Wilson M, Sikora M, Morganroth M, Smith M, Farooqui N, Lesch N, Jain N, Parikh N, Hartog N, Luthin P, Stewart P, O’Connor P, Schochet P, Goldberg P, Patel P, Chinthrajah R, Sidhu R, Ayinla R, Brown R, Stadtler R, Wachs R, Balkissoon R, Duplantier R, Puente R, Settipane R, Mustafa S, Surani S, Jawad S, Adams S, Villegas S, Al-Farra S, Subramanian S, Bains S, Kelsen S, Wise S, Estrella-Eades S, Smith S, Qureshi T, Chen T, Kelbel T, Miller T, Jain V, Soong W, Soler X, Mattar Z. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2263-2274.e5. PMID: 32387166, DOI: 10.1016/j.jaip.2020.02.042.Peer-Reviewed Original ResearchConceptsAsthma controlAsthma Control Test scoresAsthma control toolPhysician-diagnosed asthmaCut pointsLogistic regression analysisAsthma impairmentExacerbation historyAsthma severityFuture exacerbationsTest-retest reliabilityRisk QuestionnaireSymptom impairmentAsthmaSpecialty practicePatientsRisk questionsGlobal InitiativeImpairmentAirQRisk increaseCharacteristic curveExacerbationRegression analysisComposite measure
2019
Biomarkers, Targeted Therapies, Biologics, and Bronchial Thermoplasty
Mohan A, Grace J, Mainardi A, Chupp G, Lugogo N. Biomarkers, Targeted Therapies, Biologics, and Bronchial Thermoplasty. Respiratory Medicine 2019, 123-153. DOI: 10.1007/978-3-030-20812-7_8.Peer-Reviewed Original ResearchSevere asthmaBronchial thermoplastyBiologic therapySurrogate markerOral corticosteroid exposureHeterogeneous inflammatory diseaseIdentification of respondersMultiple pathologic mechanismsAsthma controlCorticosteroid exposureDisease activityAsthma symptomsAsthma therapyPredictive markerInflammatory diseasesPrognostic markerTargeted therapyCurrent biomarkersPathologic mechanismsAsthmaDrug AdministrationParticular patientPatientsTherapyAdvanced therapies